Classification of neurological abnormalities in children with congenital melanocytic naevus syndrome identifies magnetic resonance imaging as the best predictor of clinical outcome by Waelchli, R et al.
PAEDIATRIC DERMATOLOGY
BJD
British Journal of Dermatology
Classification of neurological abnormalities in children with
congenital melanocytic naevus syndrome identifies
magnetic resonance imaging as the best predictor of
clinical outcome
R. Waelchli,1 S.E. Aylett,2,3 D. Atherton,1 D.J. Thompson,4 W.K. Chong5 and V.A. Kinsler1,6
1Paediatric Dermatology, 2Neurosciences, 4Paediatric Neurosurgery and 5Paediatric Neuroradiology, Great Ormond St Hospital for Children, London, U.K.
3Neurosciences Unit and 6Genetics and Genomic Medicine, UCL Institute of Child Health, London, U.K.
Correspondence
Veronica A. Kinsler.
E-mail: v.kinsler@ucl.ac.uk
Accepted for publication
19 April 2015
Funding sources
R.W. was funded by the OPO Foundation; the
Gottfried und Julia Bangerter-Rhyner Foundation;
and University Children’s Hospital Zurich Founda-
tion. V.K. was funded by the Livingstone Skin
Research Centre, and by the National Institute for
Health Research Biomedical Research Centre at
Great Ormond Street Hospital for Children NHS
Foundation Trust and University College London.
Conflicts of interest
None declared.
DOI 10.1111/bjd.13898
Summary
Background The spectrum of central nervous system (CNS) abnormalities described
in association with congenital melanocytic naevi (CMN) includes congenital,
acquired, melanotic and nonmelanotic pathology. Historically, symptomatic CNS
abnormalities were considered to carry a poor prognosis, although studies from
large centres have suggested a much wider variation in outcome.
Objectives To establish whether routine MRI of the CNS is a clinically relevant
investigation in children with multiple CMN (more than one at birth), and to
subclassify radiological abnormalities.
Methods Of 376 patients seen between 1991 and 2013, 289 fulfilled our criterion
for a single screening CNS MRI, which since 2008 has been more than one CMN
at birth, independent of size and site of the largest naevus. Cutaneous phenotyp-
ing and radiological variables were combined in a multiple regression model of
long-term outcome measures (abnormal neurodevelopment, seizures, require-
ment for neurosurgery).
Results Twenty-one per cent of children with multiple CMN had an abnormal
MRI. Abnormal MRI was the most significant predictor of all outcome measures.
Abnormalities were subclassified into group 1 ‘intraparenchymal melanosis alone’
(n = 28) and group 2 ‘all other pathology’ (n = 18). Group 1 was not associated
with malignancy or death during the study period, even when symptomatic with
seizures or developmental delay, whereas group 2 showed a much more complex
picture, requiring individual assessment.
Conclusions For screening for congenital neurological lesions a single MRI in mul-
tiple CMN is a clinically relevant strategy. Any child with a stepwise change in
neurological/developmental symptoms or signs should have an MRI with contrast
of the brain and spine to look for new CNS melanoma.
What’s already known about this topic?
• Multiple congenital melanocytic naevi (CMN; more than one lesion at birth) can
be associated with abnormalities of the central nervous system (CNS). The spec-
trum of these abnormalities includes congenital and acquired pathologies, melan-
otic and nonmelanotic lesions, rendering the term ‘CMN syndrome’ more
appropriate than ‘neurocutaneous melanosis’.
• Symptomatic CNS abnormalities were previously thought to carry a universally
poor prognosis, although cohort data in the last decade have argued against this.
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What does this study add?
• A single CNS magnetic resonance imaging scan in multiple CMN, independent of
projected adult size or site of the largest naevus, and ideally in the first 6 months
of life, is currently an appropriate screening strategy.
• An abnormal result is a better statistical predictor of clinical outcome than cuta-
neous phenotype.
• Clinical management is altered as a result of the radiological result.
Congenital melanocytic naevi (CMN) can be single or multiple
at birth. Multiple CMN, defined as more than one CMN at
birth, can be associated with neurological abnormalities of the
central nervous system (CNS), traditionally termed neurocuta-
neous melanosis (NCM). Patients with multiple CMN also
have an increased risk of primary melanoma developing in the
CNS or in the skin.1 The underlying cause of multiple CMN
and so-called NCM was recently found to be mosaicism for
heterozygous activating mutations in codon 61 of NRAS, a
developmental gene and oncogene involved in the control of
key cell signalling pathways.2 However, the onset of mela-
noma requires further genetic events.2
Although neurological abnormalities are well established as
the most common extracutaneous manifestations of mosaicism
in children with multiple CMN, with an incidence ranging
from 10% to 33% in clinical studies,3–5 the blanket term
‘NCM’ has been applied to all abnormalities, with no system-
atic subclassification. This term was originally proposed by
Rokitansky in 1861 as a description of autopsy findings in a
single case with fatal melanotic leptomeningeal disease, which
we would now recognize as melanoma. With the advent of
magnetic resonance imaging (MRI) and the description of the
characteristic signal for melanin,5,6 the spectrum of described
neurological abnormalities has expanded to include congenital
and acquired, melanotic and nonmelanotic lesions, with widely
varying clinical outcomes ranging from benign quiescent
lesions to fatal malignancy. The most common abnormality on
MRI in either asymptomatic populations or prospectively col-
lected populations is isolated intraparenchymal melanosis (foci
of melanin-containing cells in the brain parenchyma),3,7 previ-
ously thought to be secondary only to overlying invasive lep-
tomeningeal disease. Although this can occur in the context of
malignant disease, several histopathological studies have proven
the presence of congenital melanotic parenchymal deposits
without involvement of the overlying meninges. The melanin
in these lesions is produced within neurons and glia rather than
melanocytes, and there are subtle signs of focal cortical dys-
plasia within these lesions.8–13
Other less frequent neurological diagnoses include syringo-
myelia, nonmalignancy-related hydrocephalus, tumours
(including ependymoma, meningioma, astrocytoma, choroid
plexus papilloma and pineal germinoma) and malformations
such as Dandy–Walker andArnold–Chiarimalformations.5,6,13–15
The risk of congenital neurological abnormalities in children
with CMN increases with the size of the largest CMN and the
total number of naevi.3,4,16 These two variables are intimately
but complexly connected, with the increasing size of the lar-
gest naevus usually but not always associated with increasing
numbers of total naevi. As such, these variables confound
each other within logistic regression models where both are
used. As both these measures are relatively inaccurate it is dif-
ficult to say with confidence which is most reliable, but, in
our experience, the projected adult size of the largest lesion is
a more robust measurement in statistical models.
There have been other confounders in the study of neurolo-
gical abnormalities in CMN. For example, CMN distribution
over the posterior axis (overlying the head, neck or spine) is
no longer considered to be a risk factor for neurological
abnormalities but rather a confounder for size of the main
CMN.3,17,18 Furthermore, primary CNS melanoma can develop
either in the parenchyma or in the leptomeninges, and this
data has usually been amalgamated with data on congenital
abnormalities. Where primary melanoma occurs the clinical
picture is of sudden clinical deterioration, usually with symp-
toms of raised intracranial pressure and/or of spinal compres-
sion.
It is commonly suggested in the literature that the out-
come of children with ‘symptomatic NCM’ is extremely
bleak,16,19 with near-certain mortality. However, more recent
larger studies have reported symptoms in many individuals
with MRI abnormalities where the outcome has not been
fatal.3,14,15 The original perception is based partly on reports
of neurological involvement prior to the advent of MRI, all
of which were at autopsy and were therefore likely malig-
nant processes rather than congenital abnormalities, and
partly on a lack of large prospective studies of children with
this rare condition.
The primary aim of this study was therefore to subclassify the
CNS congenital radiological abnormalities on the first screening
scan in a large cohort of children with CMN, and to correlate
these findings with clinical outcome measures. A secondary aim
was to re-evaluate our 2008 guidelines for imaging of the CNS
in order to assess whether these have proved clinically useful
over the last 6 years.
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Patients and methods
Patients
Patients in this cohort were seen sequentially in the paedi-
atric dermatology department at Great Ormond Street Hospi-
tal between 1991 and 2013, and followed prospectively.
Therefore, this study includes the majority of patients studied
in two previous publications by our group,3,20 and, owing
to the larger patient cohort and systematic sequential collec-
tion of patients in recent years, supplants the previous studies
from the point of view of recommendations. All patients
with an abnormal MRI scan were also evaluated by a paedi-
atric neurologist and followed prospectively, which included
a detailed neurodevelopmental and neurological history and
examination. In total, 636 new patients were seen (see
Fig. 1), of whom 376 were deemed after a review of the
notes to have had sufficient clinical data collected at the first
visit for them to be included in this analysis. The total of
376 includes all new patients (n = 291) seen sequentially
since 2006, after a standardized clinical data collection form
was introduced. In total, 289 of the 376 patients fulfilled
our criteria for MRI of the CNS, and 271 had successfully
completed scans at the time of analysis. The MRI scans were
undertaken almost exclusively under sedation only, rather
than under general anaesthesia, as is standard practice in our
hospital for children < 1 year of age. Where scans were not
completed this was due to either failure of sedation of the
patient or failure to attend for the appointment on two occa-
sions. Images were analysed by a paediatric neuroradiologist
with expertise in CMN, who was aware of the diagnosis of
multiple CMN but who did not have details on clinical
outcomes.
Inclusion criteria
Before 2008 the criteria for MRI were a CMN > 2 cm overly-
ing the spine or brain, or a CMN elsewhere of at least the size
of the patient’s hand. After results published in 2008,21 the
criteria were changed to include only those with multiple
CMN (i.e. more than one at birth) independent of the site and
size of the lesions, if presenting before the age of 2 years. If
the patient is older than 2 years at first presentation and neu-
rologically normal we do not perform a screening MRI as
most congenital lesions requiring treatment should have
declared themselves by this stage. Urgent MRI is performed at
any age with any CMN if neurological symptoms occur. Only
four children were neurologically symptomatic at the time of
the referral to our department.
Outcomes
The phenotypic variables analysed were radiological (MRI result
and subsequent classification) and clinical (largest CMN
projected adult size, total number of naevi at birth and at enrol-
ment). Adverse outcome measures were seizures, neurodevelop-
mental problems, whether neurosurgery was required, primary
CNS malignant melanoma, and death from primary CNS mela-
noma or primary cutaneous melanoma. Neurodevelopmental
problems were defined as those diagnosed by a paediatrician or
a paediatric neurologist, or officially by school assessment and
requiring an educational intervention.
Nonfatal melanoma was not included as an outcome mea-
sure as there were no cases in this cohort where melanoma
was not fatal. Statistical modelling of outcome measures was
performed by multiple logistic regression, considering the
whole cohort together. For statistical analysis of the effect of
Fig 1. Flow chart of numbers and timings of patients seen and included in this study. MRI, magnetic resonance imaging.
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guidelines introduced in 2008, the frequency of scans ordered
and the percentage of abnormal scans was compared in the
pre- and post-2008 cohorts by a two-tailed Fisher’s exact test.
Results
In total, 289 children fulfilled the criteria for MRI of the
whole CNS. Two hundred and seventy-one of these scans
were performed successfully. The mean and median ages at
time of first MRI were 15 and 06 years, respectively (SEM
02), and the mean and median length of follow-up was 110
and 85 years, respectively (SEM 04). The cutaneous
phenotype spectrum of this tertiary referral centre cohort is
skewed towards the severe end, with 62% of the patients hav-
ing a CMN of > 20 cm projected adult size, and 41% of
> 40 cm (Table 1).
Overall, 46 of 271 (17%) MRIs from the whole cohort
were abnormal, rising to 21% in the post-2008 criteria cohort
(nonsignificant difference; see below for comparison of pre-
and post-2008 data). Abnormalities were subclassified into
group 1, ‘intraparenchymal melanosis alone’ (n = 28), as this
is the most common single finding in patients with CMN, and
group 2, ‘other CNS pathology’ (n = 18). Group 2 was too
small to subdivide for analysis, as it included a wide variety of
different CNS pathologies (Table 2).
Any radiological abnormality (as a binary variable, normal
vs. abnormal MRI) was a stronger predictor than projected
adult size for all outcome measures: seizures [odds ratio
(OR) 134, 95% confidence interval (CI) 47–382], neu-
rodevelopmental problems (OR 30, 95% CI 13–70) and
requirement for neurosurgery (OR 710, 95% CI 89–5673)
(Table 3). CNS melanoma and death were not modelled as
the numbers are low. When projected adult size of the lar-
gest CMN was included in these models as a categorical vari-
able (< 10, 10–20, 20–40, 40–60 and > 60 cm), the
variable as a whole was only significant for neurodevelop-
mental abnormalities (P = 003). Sex (as a binary variable,
male = 1) was not found to be significant in these models.
For the full regression analysis, please see Appendix S1 (Sup-
porting Information).
Seizures and abnormal neurodevelopment were seen in a
minority of the normal MRI group; however, not only were
these numbers small, but the seizures were also a temporary
problem and/or easy to control with a single medication, and
the neurodevelopmental abnormalities were mild, compatible
with normal schooling. This is a notably milder clinical phe-
notype than that seen in those with seizures or neurodevelop-
mental abnormalities in the other radiological groups
(Table 3). Of note, one patient with a normal initial MRI scan
developed primary CNS melanoma requiring neurosurgery
and later died from primary CNS disease (Fig. 2). This patient
was first scanned in the late 1990s and the quality of MRI has
improved since then. Therefore, it is possible that there was a
neurological disease present that was below the resolution of
scanning, as has been shown histologically.13
Of those with abnormal scans, there was a striking differ-
ence between the two subgroups in clinical outcomes. While
a substantial proportion of patients in group 1 had neurologi-
cal symptoms, namely 259% with seizures, and 286% with
neurodevelopmental abnormalities (not significantly different
from group 2), there were no patients with melanoma in this
subgroup, and no deaths. Although CNS melanoma must be
possible in this group the risk appears to be low in childhood.
Furthermore, we can conclude that in patients with intra-
parenchymal melanosis alone, symptoms can be related to that
congenital disease and do not necessarily equate with malig-
nancy or death. Therefore, with classical radiological features
intraparenchymal melanosis alone does not require surgical
intervention. Because of this subtlety – the differentiation
between symptomatic congenital disease and new onset of
symptoms from CNS melanoma – we would continue to rec-
ommend a repeat MRI of the CNS in any child who presents
Table 1 Frequencies of different cutaneous phenotypic features in the
study cohort
Projected adult size of largest naevus (cm) n = 265
< 10 42 (159)
10–20 50 (189)
20–40 55 (208)
40–60 46 (174)
> 60 64 (242)
No one larger lesiona 8 (302)
Site of largest CMN n = 157
Face 9 (57)
Scalp 19 (121)
Trunk 82 (522)
Limb 18 (115)
Scalp/neck/trunk 13 (83)
Face/scalp 12 (76)
No one larger lesiona 4 (26)
Total number of other naevi
at birth (previously termed satellites)b
n = 165
0 14 (85)
< 10 54 (327)
10–20 33 (200)
20–25 30 (182)
50–100 18 (109)
100–200 10 (61)
> 200 6 (36)
Data are n (%). CMN, congenital melanocytic naevi. aIndividuals
with ‘no one larger lesion’ do not have one naevus clearly big-
ger than all the others but rather a collection of similar-sized
lesions. This phenotype used to be called ‘multiple CMN’ but
owing to the normal understanding of the word ‘multiple’ we
think this term is confusing and best avoided in this context.
bThe term ‘satellite naevus’ is sometimes used to mean any other
naevus on a patient with CMN which was not the largest naevus.
We no longer use this term as it implies some sort of hierarchy
and geographical relationship between the largest naevus and the
smaller naevus,22 and all these are, in fact, CMN that have arisen
from the same postzygotic mutation and may not necessarily be
close to each other. Within the frustrating limits of the current,
relatively inaccurate classification system for CMN we therefore
prefer to count the total number of naevi.
© 2015 The Authors. British Journal of Dermatology
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with new neurological symptoms. This can then be compared
with baseline scans to look for new lesions or progression.
The clinical outcome pattern in group 1 was different to
that of group 2, where both the requirement for neurosurgery
and the mortality rate from CNS melanoma was substantial
(Table 3). The requirement for neurosurgery in group 2 was
significantly higher compared with group 1 (Fisher’s exact test
P < 001), but the mortality rate from CNS melanoma did not
differ, perhaps owing to low numbers (Fisher’s exact
P = 006). However, group 2 was very heterogeneous. The
clinical symptoms in this subgroup ranged from none to mild
speech delay to severe global delay (Table 2). Three of the 18
patients presented with an isolated benign nonmelanotic CNS
tumour (patients 6, 9 and 13; see Table 2), all of which
were removed by neurosurgery with no further sequelae.
Others in this group had leptomeningeal disease, and while
in four cases this was a progressive malignant process result-
ing in death, it is important to note that five patients have
stable nonprogressive leptomeningeal disease (patients 3, 7,
8, 11 and 14; see Table 2), all involving focal lesions of
unknown histology, which are, in some cases, quite extensive
(Fig. 3). In all of these cases the lesions are currently
Table 3 Frequencies and odds ratios for each of the adverse clinical outcomes with respect to radiological findings. Where the numbers do not
equal the total numbers for the radiologically classified group this is due to missing data for a very few patients on outcomes.
Normal MRI
Intraparenchymal
melanosis only Other pathology
OR (95% CI) for modelling
these outcomes by MRI result
(binary  normal/abnormal)
Neurodevelopmental problems 26/226 (115%) 8/28 (286%) 7/17 (412%) 30 (13–70)
Seizures 6/220 (27%) 7/27 (259%) 4/16 (25%) 134 (47–382)
Requirement for neurosurgery 1/226 (04%) 0/27 (0%) 11/8 (611%) 710 (89–5673)
Data are n (%) unless otherwise indicated. MRI, magnetic resonance imaging; OR, odds ratio; CI, confidence interval.
(a) (b)
(c)
Fig 2. (a) Comparison of the percentage of patients in whom a magnetic resonance imaging (MRI) scan was performed (white column) and not
performed (black column) before and after 2008. By excluding those with only a single congenital melanocytic naevus (CMN), independent of
size or site, the introduction of guidelines in 2008 has significantly reduced the percentage of patients scanned routinely. However, the percentage
of abnormal scans is not significantly altered, suggesting that we have become more efficient at detecting the same rate of abnormalities. (b)
Comparison of the percentage of patients with a normal MRI result (white column) with those with an abnormal result (black column) before
and after 2008. The introduction of guidelines in 2008 has not significantly altered the percentage of abnormal scans detected, which implies that
we are not failing to detect significant numbers of abnormalities. (c) Subclassification of the radiological abnormalities in this cohort of children
with CMN and correlation with the incidence of the different clinical outcome measures in each group. CNS, central nervous system.
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asymptomatic. Furthermore, in patient 5 (aged 10 years at
the time of writing) there is diffuse leptomeningeal disease
indistinguishable radiologically from the four patients with
progressive malignant process, which developed over the first
year of life but which has not changed since then. Therefore,
patients in group 2 have to be assessed on an individual
basis, and our experience suggests that radiological progres-
sion or stability are useful guides to management. This is par-
ticularly useful in a condition where histology is often not
reliable. New genetic tests on leptomeningeal lesions are
likely to be helpful in the future to distinguish between
benign and malignant lesions.
(a) (b) (c) (d)
(e) (f)
(g)
Fig 3. (a) Intradural extramedullary disease, presumed leptomeningeal, dorsal to the spinal cord. (b) Enhancing intradural extramedullary disease,
presumed leptomeningeal, dorsal to the spinal cord. (c) Intradural extramedullary disease, presumed leptomeningeal, dorsal to the spinal cord. (d)
Prominent central canal of the lower thoracic cord. These lesions have not been biopsied and therefore no exact diagnosis is available. However,
in all cases shown the patients do not exhibit spinal symptoms or signs, and magnetic resonance imaging (MRI) appearances have been stable
since birth, with follow-up now at ages 5, 6, 10 and 16 years. (e) Extensive intraparenchymal melanosis of the cerebellum and focal melanosis of
left thalamus. (f) Pre- and postgadolinium-enhanced MRI showing meningioma in left sylvian fissure. (g) Pre- and postgadolinium-enhanced MRI
showing Dandy–Walker malformation with congenital leptomeningeal disease at 13 days. Further progression of leptomeningeal disease at
22 months. Intraparenchymal melanoma of left sylvian fissure at the age of 24 months, which appears to have developed from leptomeningeal
infiltration, although this is not always the case.
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Comparison of our practice and results before and after the
publication of guidelines on MRI in 2008 identified that we
are doing significantly fewer scans as a proportion of new
patient referrals since these guidelines were introduced
(Fig. 2), whereas the detection rate of abnormalities in those
having scans has not significantly changed (small increase)
(Fig. 2). Importantly, the clinical phenotype profile of the
cohort has not changed since the guidelines were changed.
Therefore, we are confident that on the basis of this large
prospective dataset the 2008 guidelines are fit for purpose,
allowing detection of neurological abnormalities without per-
forming unnecessary scans in very low-risk individuals. How-
ever, as with all guidelines, there must always be room for
clinical judgement.
Discussion
We propose the continued use of the term ‘CMN syndrome’
for CMN with extracutaneous features, which we deem more
appropriate than NCM due to nonmelanotic CNS lesions and a
causative single gene defect for the cutaneous and neurological
findings. This term also brings CMN into line with terminol-
ogy used for other congenital naevi, where, for example, an
epidermal naevus associated with extracutaneous features is
termed ‘epidermal naevus syndrome’.
MRI of the CNS in children with CMN was originally
started in 1988 at Great Ormond St Hospital as a research pro-
ject in order to try to delineate the spectrum of disease in par-
allel with other centres, and to exploit the newly described
sensitivity of MRI specific to melanin. This research project
produced its first set of preliminary guidelines for the use of
MRI in 2008, where the principal recommendation was to
stop performing a routine scan for children with only a single
CMN at birth; however, as is correct practice, these guidelines
have now been audited to see if they continue to be fit for
purpose. In the interim, we have continued to see new
patients and have continued to expand our cohort of prospec-
tively collected long-term outcome data. This cohort is now
large enough that we can start to answer the question of
whether a single screening CNS MRI is a valuable clinical test
in patients with CMN; in other words, does it alter our man-
agement?
The results presented herein show that routine MRI of the
CNS in children with two or more CMN at birth, independent
Fig 4. Great Ormond Street Hospital management guidelines for children with congenital melanocytic naevi (CMN). MRI, magnetic resonance
imaging; CNS, central nervous system.
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of projected adult size or site of the largest CMN, and under-
taken within the first year of life (ideally within the first
6 months, as myelination obscures the signal for melanin), is
the best predictor of neurodevelopmental abnormalities, sei-
zures and the requirement for neurosurgery in childhood. It
is, of course, not impossible that a child with a single CMN
could have a neurological abnormality on MRI; however,
comparison of our data from before and after the publication
of the 2008 guidelines has found that while the percentage of
children scanned has significantly decreased, there has been
no significant change in the percentage of abnormal scans.
This suggests that the guidelines are currently fit for purpose
in terms of not missing large numbers of children with seri-
ous intracranial pathology.
Clinical management was altered substantially by the radio-
logical results. Firstly, brain and spinal tumours were resected
when causing compression, and follow-up scans were used to
monitor recurrence. Secondly, ventriculoperitoneal shunts
were inserted where there was hydrocephalus, and follow-up
scans used to monitor position and progression/resolution.
Thirdly, children with leptomeningeal disease were monitored
by MRI, and where it progressed a biopsy was taken to look
for melanoma histologically and genetically. Lastly, where
intraparenchymal melanosis alone was detected the children
were seen by a paediatric neurologist at least once, and by a
developmental neurologist on an annual basis, and where
intervention was required (e.g. speech therapy, occupational
therapy, behavioural intervention), this was instituted
promptly as for any child with these clinical problems.
For many years we have recognized that the clinical out-
come of children with ‘symptomatic’ neurological disease has
not necessarily been poor, despite the majority of publications
on CMN still professing this idea. Therefore, the secondary
aim of this study was an attempt at subclassification of radio-
logical abnormalities, and to correlate this with outcome mea-
sures. This has identified a high-risk group frequently
requiring neurosurgery in early childhood, and possibly at
higher risk of death from CNS melanoma (although this has
not been modelled statistically as the numbers of deaths are
small) (group 2), while providing reassurance that the most
common finding of intraparenchymal melanosis alone is a
nonmalignant condition, even when symptomatic (group 1).
We propose that those with normal MRI results do not
require either routine repeat MRI or formal neurodevelopmen-
tal follow-up; that those in in group 1 do not require routine
repeat MRI but do require neurodevelopmental follow-up on
an annual basis; and that those in group 2 should have regular
repeat MRI and regular neurological follow-up (Fig. 4). The
periodicity of these interventions in group 2 would be
decided by the multidisciplinary team, depending on the MRI
findings; however, we would suggest that those with lep-
tomeningeal disease need to monitored extremely closely initi-
ally as this disease can spread rapidly. However, if the
findings are stable this intensity could be relaxed. Very impor-
tantly, any change in neurological status at any age should
always trigger a repeat MRI, independent of the initial MRI
findings.
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